CAMBRIDGE, Mass., Feb. 27, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today announced that management will present at the following upcoming investor conferences.
- Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 12:00 p.m. ET. The fireside chat will be held at the Boston Marriott Copley Place in Boston.
- Barclays Global Healthcare Conference on Tuesday, March 13, 2018 at 2:05 p.m. ET. The brief Company overview and subsequent fireside chat will be held at the Loews Miami Beach Hotel in Miami.
The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]


SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 



